CNS Market Analysis 2002: Commercial Viability of Four Dynamic CNS Markets

Introduction

The CNS therapy area is becoming a crucial sector for many major pharmaceutical manufacturers. Key players such as Pfizer, GlaxoSmithKline and Merck, now derive large proportions of their revenues from CNS markets, with 2002 delivering strong growth in most areas. This Brief compares the commercial viability of four important CNS markets in 2002 including Alzheimer's disease and nociceptive pain 

Scope

Overview of the Alzheimer's disease (AD), antipsychotics, multiple sclerosis (MS) and nociceptive pain market dynamics in 2002 

2000 to 2002 global sales analysis of leading brands in these therapy areas 

Analysis of the commercial viability of these markets in 2008 

Commercial viability is quantified by comparing the level of unmet need, competitive intensity, and commercial attractiveness of these markets in 2008 

Report Highlights

In 2002, the AD, antipsychotics, MS, and nociceptive pain markets boasted double-digit growth making them attractive avenues for investors to explore. The MS market, for example, grew 21% over 2002, allowing Biogen to enjoy - for the first time - blockbuster revenues from its market-leading drug Avonex 

The four therapy areas vary significantly in terms of unmet need, competitive intensity and market attractiveness in 2008. For example, the AD and MS have the highest level of unmet need, whereas nociceptive pain is the most attractive in terms of patient potential and market revenues. 

Reasons to Purchase

Assess the level of unmet need between four lucrative CNS markets 

Enhance market penetration strategy by understanding the competitive intensity of each market by 2008 

Optimize your CNS franchise by comparing the attractiveness of these CNS therapy areas in terms of patient potential, market size, and market growth 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a108